Shares of Audentes Therapeutics Inc (NASDAQ:BOLD) have been assigned a consensus recommendation of “Buy” from the fourteen ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $34.36.

A number of brokerages recently commented on BOLD. Zacks Investment Research cut shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. BidaskClub raised shares of Audentes Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, March 6th. William Blair reissued a “hold” rating on shares of Audentes Therapeutics in a research note on Wednesday, February 27th. Chardan Capital raised shares of Audentes Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $35.00 to $40.00 in a research note on Monday, February 25th. Finally, HC Wainwright reissued a “buy” rating and issued a $33.00 price objective on shares of Audentes Therapeutics in a research note on Friday, January 11th.

Shares of NASDAQ BOLD opened at $36.66 on Tuesday. The stock has a market capitalization of $1.52 billion, a P/E ratio of -10.78 and a beta of 1.90. Audentes Therapeutics has a 52 week low of $17.95 and a 52 week high of $46.18.

Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings data on Wednesday, February 27th. The biotechnology company reported ($0.84) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.91) by $0.07. During the same quarter last year, the firm earned ($0.82) earnings per share. Equities analysts anticipate that Audentes Therapeutics will post -3.85 earnings per share for the current year.

In other Audentes Therapeutics news, VP Suyash Prasad sold 10,000 shares of the firm’s stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $30.06, for a total transaction of $300,600.00. Following the sale, the vice president now directly owns 28,236 shares of the company’s stock, valued at approximately $848,774.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Louis G. Lange sold 32,000 shares of the firm’s stock in a transaction dated Monday, December 24th. The stock was sold at an average price of $18.62, for a total transaction of $595,840.00. Following the sale, the director now directly owns 325,799 shares in the company, valued at $6,066,377.38. The disclosure for this sale can be found here. Insiders have sold a total of 63,000 shares of company stock worth $1,526,440 over the last ninety days. 6.60% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in the business. NumerixS Investment Technologies Inc lifted its holdings in shares of Audentes Therapeutics by 1,200.0% during the 4th quarter. NumerixS Investment Technologies Inc now owns 1,300 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 1,200 shares during the period. Amundi Pioneer Asset Management Inc. purchased a new position in shares of Audentes Therapeutics during the 4th quarter worth about $92,000. Great West Life Assurance Co. Can lifted its holdings in shares of Audentes Therapeutics by 96.0% during the 4th quarter. Great West Life Assurance Co. Can now owns 4,726 shares of the biotechnology company’s stock worth $97,000 after acquiring an additional 2,315 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in shares of Audentes Therapeutics by 46.1% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,280 shares of the biotechnology company’s stock worth $138,000 after acquiring an additional 1,983 shares during the period. Finally, Legal & General Group Plc lifted its holdings in shares of Audentes Therapeutics by 34.5% during the 4th quarter. Legal & General Group Plc now owns 6,632 shares of the biotechnology company’s stock worth $141,000 after acquiring an additional 1,700 shares during the period.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Story: Trading Stocks – What are percentage gainers?

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.